11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
Mirum Pharmaceuticals Inc. (MIRM)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 77,263 | $3,480,698 | -34% | 1.54% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 23,500 | $1,058,675 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.93 | 21 | 168,672 | 2025-03-17 | Filing | ||
| $44.11 | 528 | 168,651 | 2025-03-14 | Filing | ||
| $43.77 | 963 | 168,123 | 2025-03-11 | Filing | ||
| $43.37 | 577 | 167,160 | 2025-03-10 | Filing | ||
| $42.66 | 758 | 166,583 | 2025-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.45 | 2,415 | 2,426 | 2025-03-18 | Filing | ||
| $44.36 | 1,806 | 4,841 | 2025-03-17 | Filing | ||
| $44.75 | 2,789 | 6,647 | 2025-03-17 | Filing | ||
| $44.33 | 50,111 | 9,436 | 2025-03-17 | Filing | ||
| $44.21 | 2,900 | 6,647 | 2025-03-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,339,557 | $150,447,043 | 0% | |
| 2. | 2,540,061 | $114,429,748 | 0% | |
| 3. | 35,000,000 | $56,936,250 | 1.9% | |
| 4. | 27,958,000 | $45,472,783 | 1.46% | |
| 5. | 778,244 | $35,059,892 | 0.04% |
News See All
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2024 Earnings Call Transcript
Operator: Hello, and welcome to Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update. My name is Elliot, and I'll be your coordinator today.
10 Best Performing Mid Cap Stocks to Buy According to Analysts
On February 7, Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2024 Earnings Call Transcript
Operator: Hello everyone, and welcome to the Mirum Pharmaceuticals' Third Quarter 2024 Financial Results and Business Update. My name is Seb [ph] and I'll be the operator for your call today.
8 Best Small-Cap Growth Stocks to Buy According to Analysts
During the third quarter of 2024, small-cap stocks represented by the Russell 2000 Index made a strong comeback after a somewhat disappointing second quarter.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Mirum Pharmaceuticals First Quarter 2024 Financial Results and Business Update. My name is Terry, and I will be the conference operator today.
Corporate Insiders Are Selling These 5 Small-Cap Stocks
This article presents an overview of Corporate Insiders Are Selling These 5 Small-Cap Stocks. For a detailed overview of such stocks, read our article, Corporate Insiders Are Selling These 10 Small...
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.33.
Should You Invest in Mirum Pharmaceuticals (MIRM)?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2023 Earnings Call Transcript
Operator: Good afternoon. I would like to welcome you all to the Mirum Pharmaceuticals Conference Call. My name is Brika and I'll be the event specialist running today's call with you.